https://orcid.org/0000-0001-7442-1746
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Context
Inflammatory and immune pathways play a crucial role in the pathophysiology of non-alcoholic fatty liver disease (NAFLD). Sitagliptin blocks the dipeptidyl peptidase-4 (DPP-4) enzyme, mechanisms that alter inflammatory pathways and the innate immune system, and by which Sitagliptin affects the pathogenesis of NAFLD weren’t previously discussed.
Objective
This study aims to understand the interaction between Sitagliptin and innate immune response in order to meliorate NAFLD.
Methods
Thirty- two Wistar male albino rats were categorised into four groups. Rats have received a standard diet or a high-fat diet either with or without Sitagliptin. Serum HMGB1, protein and mRNA expressions of hepatic TLR4 and NF-κB, inflammatory cytokines, and histopathological changes were analysed.
Results
An ameliorative action of Sitagliptin in NAFLD was demonstrated via decreasing HMGB1-mediated TLR4/NF-κB signalling in order to suppress inflammation and reduce insulin resistance.
Conclusion
Sitagliptin may in fact prove to be a beneficial therapeutic intervention in NAFLD.
Acknowledgements
The research group shows gratitude to all participants and the entire staff of physiology and biochemistry departments, Benha faculty of medicine, Benha University for their dedicated and conscientious collaboration and assistance.
Ethical approval
The animal study was approved by the Local Ethical Committee, Benha Faculty of Medicine, Egypt.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Author contributions
All authors of this research paper have contributed equally to the planning, execution, or analysis of this study.
Data availability statement
All relevant raw data will be freely available by the authors.